e-learning
resources
Barcelona 2013
Monday, 09.09.2013
COPD mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes
V. Pinto-Plata, M. Divo, Y. Tesfaigzi, H. Peterson, V. Calhoum, D. Holloway, Y. Wang, C. Owen, B. Celli (Boston, Albuquerque, United States Of America)
Source:
Annual Congress 2013 –COPD mechanisms
Session:
COPD mechanisms
Session type:
Thematic Poster Session
Number:
2140
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Pinto-Plata, M. Divo, Y. Tesfaigzi, H. Peterson, V. Calhoum, D. Holloway, Y. Wang, C. Owen, B. Celli (Boston, Albuquerque, United States Of America). Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes. Eur Respir J 2013; 42: Suppl. 57, 2140
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers
Source: International Congress 2014 – Markers
Year: 2014
Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort
Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Year: 2018
Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients
Source: Annual Congress 2010 - COPD: symptoms and staging
Year: 2010
Novel method of expressing serum biomarkers profiling in COPD patients: The heatmap-clinical pattern profile
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
Relation of plasma osteopontin levels with the clinical course in patients with COPD
Source: International Congress 2014 – Systemic and airway biomarkers
Year: 2014
Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Stable state MR-proadrenomedullin level in COPD patients; a validation study
Source: International Congress 2014 – Comorbidities
Year: 2014
Individual dynamic of inflammatory markers as indicators of COPD treatment effectiveness
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study
Source: Annual Congress 2009 - Biomarkers and biology in COPD
Year: 2009
Relationship between plasma amino acid levels and lung function decline in patients with COPD
Source: Annual Congress 2013 –COPD: markers and inflammation
Year: 2013
COPD related fatigue (COPD-RF) as a patient centred outcome tool in COPD: Various predictors and its correlation with other outcome parameters
Source: International Congress 2016 – Monitoring airway diseases with clinical tools
Year: 2016
Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap
Source: Annual Congress 2013 –Is it really asthma?
Year: 2013
Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up
Source: International Congress 2014 – Markers
Year: 2014
Serum sirtuin-1 is reduced in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021
Scales of assesment in COPD. Correlation with clinical and functional parameters
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Proteome fingerprints define groups with distinct clinico-pathological phenotypes in the U-BIOPRED asthma study
Source: International Congress 2016 – What's new in biomarker analysis?
Year: 2016
LATE-BREAKING ABSTRACT: Biomarkers of ECM turnover and clinical relevant outcomes in COPD: Results of the multicenter PROMISE study
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015
Relationship of baseline or annual change of clinical parameters on mortality in patients with COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept